Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Research Antibodies Market To Reach USD 5.33 Billion By 2027 | Reports and Data

Published

on

New York, June 29, 2020 (GLOBE NEWSWIRE) — The global research antibodies market is expected to reach USD 5.33 Billion by 2027, according to a new report by Reports and Data. Rising research activities in the field of stem cells is a significant factor driving the growth of the market. Stem cells have the capability of discerning and regenerating various kinds of cells in the human body. These cells possess the potential to cure life-threatening diseases such as oncological and blood-related disorders. Cord blood stem cells find application in the treatment of more than 80 blood-related ailments, such as Sickle Cell Disease. It is projected that over 27 million babies across the globe are born with some kind of blood disorder. As per the World Health Organization, in 2008, 100,000 children were found to be suffering from thalassemia in India.Increased funding for research and development activities is instrumental in driving the growth of the market. Investment in the healthcare R&D by the US has witnessed a growth of 18.1% between the years 2014 and 2017. In the year 2017, in the US, the overall expenditure on healthcare R&D was USD 182.30 billion. Besides, according to the 2016 financial statements of Celgene Corporation, a leading biopharmaceutical firm, the R&D expenditure grew by USD 772.8 million (21.0% more than 2015 expenses) in 2016 to USD 4.47 billion. Also, a USD 892.9 million of R&D asset acquisition spending, comprising a USD 625.0 million purchase of Engmab AG, a private firm engaged in T-cell bispecific antibodies, added to the overall R&D expenses of the Celgene.However, cost-prohibitive research antibodies and issues related to the quality of nontherapeutic antibodies may create hindrances in the growth of the market in the upcoming years.Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3270COVID-19 Impact
As the global economies are experiencing the negative impact of the Covid-19 pandemic, organizations are suffering losses, among various other challenges. Nevertheless, firms in the pharmaceutical industry are of immense importance in combatting the pandemic and are witnessing positive growth in the contagious disease landscape with the race for treatment approval therapy gaining momentum.
In April 2020, the ICMR (Indian Council of Medical Research) announced that it would fast-track funding proposals intended for immunology approaches for the treatment of coronavirus, a step to bridge the research gap in the country to combat the pandemic.Further key findings from the report suggestBy product, primary antibodies held a larger market share in 2019. Primary antibodies are those, which bind to the antigen, protein, or any substance that is intended to be studied. Primary antibodies, in immunoassays, are of prime importance to bind to the target antigen.By technology, western blotting contributed to the largest market share in 2019. The benefits of western blots comprise the capacity to detect picogram levels of protein in a sample, enabling it to be used for several applications such as an effective early diagnostic tool. Also, it lets researchers for direct labeling of primary antibodies, therefore removing the requirement of secondary antibodies.By application, oncology contributed to the largest market share in 2019. Antibody-based treatment of cancer is considered as an effective therapeutic approach for both hematologic solid tumors and malignancies. Antibodies are also beneficial in using the human immune system to fight cancer.The market in the Asia Pacific region is expected to grow at the fastest rate of 7.1% in the forecast period. The high growth of the APAC region is owing to the growth of the pharmaceutical industry, surge in R&D activities for antibodies, and acceptance of innovative methods for antibody production, among others.Key participants include Becton, Dickinson and Company, Lonza Group, Agilent Technologies, Abcam PLC, PerkinElmer, Inc., Bio-Rad Laboratories, Merck Millipore, F.Hoffmann-La Roche AG, Thermo Fisher Scientific, and Cell Signaling Technology Inc., among others.In January 2020, Abcam PLC, a leading market player, made an announcement about the acquisition of the Immunology and Proteomics business of Expedeon that comprises Innova and TGR Biosciences.BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3270For the purpose of this report, Reports and Data have segmented the global research antibodies market on the basis of product, antibody type, technology, application, end-users, and region:Product Outlook (Revenue, USD Million; 2017-2027)Primary AntibodiesSecondary AntibodiesAntibody Type Outlook (Revenue, USD Million; 2017-2027)MonoclonalPolyclonalTechnology Outlook (Revenue, USD Million; 2017-2027)Western BlottingFlow CytometryImmunofluorescenceImmunohistochemistryEnzyme-linked Immunosorbent AssayImmunoprecipitationOthersApplication Outlook (Revenue, USD Million; 2017-2027)OncologyInfectious DiseasesStem CellsNeurobiologyImmunologyOthersIndustry Vertical Outlook (Revenue, USD Million; 2017-2027)Pharmaceutical & BiopharmaceuticalAcademic & Research InstitutesContract Research OrganizationsTo identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/research-antibodies-marketRegional Outlook (Revenue, USD Million; 2017-2027)North AmericaU.SCanadaEuropeGermanyUKFranceBeneluxRest of EuropeAsia PacificChinaIndiaJapanSouth KoreaRest of Asia PacificLatin AmericaBrazilRest of Latin AmericaMEASaudi ArabiaUAERest of Middle East and AfricaTake a Look at our Related Reports:E-Prescribing Market: https://www.reportsanddata.com/report-detail/e-prescribing-marketMobile Health (mHealth) Market: https://www.reportsanddata.com/report-detail/mobile-health-mhealth-marketArtificial Intelligence in Drug Discovery Market: https://www.reportsanddata.com/report-detail/artificial-intelligence-in-drug-discovery-marketAbout Reports and DataReports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: [email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Aetina Accelerates Embedded AI with High-performance, Small Form-factor Aetina IA380E-QUFL Graphics Card

Published

on

aetina-accelerates-embedded-ai-with-high-performance,-small-form-factor-aetina-ia380e-qufl-graphics-card

TAIPEI, April 25, 2024 /PRNewswire/ — Aetina, a leading Edge AI solution provider, announced the launch of the Aetina IA380E-QUFL at Embedded World 2024 in Nuremberg, Germany. This groundbreaking product is a small form factor PCIe graphics card powered by the high-performance Intel Arc A380E GPU. 

Unmatched Power in a Compact Design
The Aetina IA380E-QUFL delivers workstation-level performance packed into a low-profile, single-slot form factor. This innovative solution consumes only 50W, making it ideal for space and power-constrained edge computing environments. Embedded system manufacturers and integrators can leverage the power of 4.096 TFLOPs peak FP32 performance delivered by the Intel Arc A380E GPU[1].
Beyond Small Size: Big Capabilities
Despite its compact size, the IA380E-QUFL offers native support for 4 mini-DisplayPort outputs and 6GB of GDDR6 memory, enabling the connection of multiple high-resolution displays (UHD). This makes the IA380E-QUFL an excellent choice for a wide range of applications, including commercial gaming, video walls, medical imaging, and visual inference for smart cities.
“The demand for slim and energy-efficient AI systems is rapidly escalating,” said Jackal Chen, Senior Product Manager at Aetina. “The Aetina IA380E-QUFL addresses this need head-on, offering a powerful GPU solution in a compact, single-slot form factor with minimal power consumption. This empowers developers to create powerful and efficient edge systems for a wide range of applications.”.
Unparalleled Commitment: 5-Year Product Supply
Acknowledging the critical need for long-term product stability in industrial applications, Aetina ensures a 5-year product supply for the Aetina IA380E-QUFL, which streamlines system roadmaps and reduces the need for costly redesign. Our commitment is aligned with Intel’s announced product plans for the Intel Arc A380E GPU.[1]
[1]https://www.intel.com/content/www/us/en/content-details/820389/intel-arc-gpu-for-the-edge-public-30-3-30.html?wapkw=Intel%20Arc%20GPU%2030-3-30&DocID=820389 Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
Photo –  https://mma.prnewswire.com/media/2395995/High_performance_Small_Form_factor_Aetina_IA380E_QUFL_Graphics_Card.jpg

View original content:https://www.prnewswire.co.uk/news-releases/aetina-accelerates-embedded-ai-with-high-performance-small-form-factor-aetina-ia380e-qufl-graphics-card-302125786.html

Continue Reading

Artificial Intelligence

IG Canada Announces Enhanced Trading Platform for Enhanced User Experience

Published

on

ig-canada-announces-enhanced-trading-platform-for-enhanced-user-experience

Meta description : Explore IG Canada’s advanced trading platform, educational resources, and robust security features. Achieve your trading goals with the innovative tools.
NOTTINGHAM, England, April 25, 2024 /PRNewswire/ — IG Canada, a premier online trading platform, is pleased to announce significant enhancements to its trading technology, designed to empower both novice and experienced traders with superior tools and resources. This development is part of IG Canada’s commitment to providing the best trading experience in the Canadian market.

IG Canada has upgraded its platform with advanced features that streamline trading processes and improve the accuracy of trade execution. These enhancements include customizable charts, a wider range of indicators, and improved mobile access, ensuring traders can operate efficiently from anywhere at any time.
Recognizing the importance of education in trading success, IG Canada has expanded its educational resources. The brokerage now offers a comprehensive learning center featuring webinars, tutorials, and articles that cater to various skill levels. These resources are designed to help traders develop robust trading strategies and improve their market knowledge.
Security remains a top priority for IG Canada. The latest updates include enhanced encryption and multi-factor authentication to protect client data and funds. These security measures provide peace of mind for traders, knowing their investments are safeguarded against potential threats.
IG Canada is a leading online brokerage that provides trading services across multiple asset classes, including forex, stocks, commodities, and indices. With a focus on innovation and customer service, IG Canada is committed to helping Canadian traders achieve their investment goals through a transparent and efficient trading environment.
In addition, IG Canada is committed to engaging with the community through upcoming webinars, live events, and partnerships with local financial experts. These initiatives are designed not only to support the growth and education of the clients but also to foster a stronger, more connected trading community in Canada.
Press Contact:Contact Name: Timothy C. SherwinEmail: [email protected] Phone: +447 441425053

View original content:https://www.prnewswire.co.uk/news-releases/ig-canada-announces-enhanced-trading-platform-for-enhanced-user-experience-302127189.html

Continue Reading

Artificial Intelligence

Sentrycs Now Part of the UK National Protective Security Authority Catalog of Security Equipment

Published

on

sentrycs-now-part-of-the-uk-national-protective-security-authority-catalog-of-security-equipment

This inclusion into the NPSA CSE marks a significant milestone in the company’s commitment to enhancing national and international airspace security and to leading the C-UAS market toward multi-layer strategy optimization and excellence.
TEL-AVIV, Israel, April 25, 2024 /PRNewswire/ — Sentrycs, a leading innovator in adaptive counter-drone solutions, is proud to announce its inclusion in the prestigious UK National Protective Security Authority Catalogue of Security Equipment (NPSA CSE).
 
Following a rigorous assessment process, Sentrycs’ cutting-edge Counter Unmanned Aerial Systems (C-UAS) solution has met the high standards set by the NPSA for Detection, Tracking, and Identification (DTI). The testing, conducted at the NPSA’s designated testing facilities in August 2023, rigorously evaluated the Sentrycs system against the NPSA’s DTI Testing and Evaluation Standard v3.1.
Sentrycs elected to be assessed under Configuration D as a 3D system with Ground Control Station (GCS) detection capability and platform identification capability, which is the most demanding test scenario with the highest number of scored parameters.
The Sentrycs system demonstrated exceptional capabilities in various security scenarios, showcasing its robustness in detecting and tracking with high accuracy and zero false alarms. The system’s innovative use of cyber techniques to extract data from targets and its streamlined human-machine interface were especially noted for their efficiency and ease of use.
“Our team is proud to have Sentrycs recognized by the UK National Protective Security Authority,” said Yoav Zaltzman, CEO of Sentrycs. “Being listed in the CSE is not just an honor; it’s a testament to our technology’s reliability and effectiveness in contributing to the ever-changing airspace security landscape.”
Sentrycs’ technology is now accessible through the NPSA CSE, providing security practitioners with verified solutions that meet the UK’s rigorous security standards. This inclusion not only underscores Sentrycs’ role in advancing security technology but also enhances its visibility and credibility on a global stage.
For more details on Sentrycs’ solutions and their impact, visit www.sentrycs.com.
For further information regarding the NPSA and the Catalog of Security Equipment, please visit the NPSA’s official website.
About Sentrycs
Sentrycs is a leader in adaptive counter-drone solutions, supported by innovative technology designed to passively identify, mitigate, and where necessary, intercept unauthorized drones custom-built for various environments – including airports, borders, prisons, critical infrastructure, and mass events. Founded in 2017, Sentrycs’ has offices in Israel and the US, serving customers worldwide. By uniting its field-proven technology and expertise in global drone environments, Sentrycs is leading the way towards a safer and more secure drone-driven future. Learn more at www.sentrycs.com
Video – https://www.youtube.com/watch?v=YBuhpTq5QuM

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/sentrycs-now-part-of-the-uk-national-protective-security-authority-catalog-of-security-equipment-302126952.html

Continue Reading

Trending